Posts

Fierce Biotech Layoff Tracker 2024: Major Layoffs Including Rapt's 40% Workforce Reduction

on
Rapt laid off 47 people representing around 40% of its workforce by the end of the third quarter, five months after a phase 2 immunology trial was placed on hold 1 Sage Therapeutics laid off at least 165 employees including 55% of its R&D workforce, along with several senior executives 1 bluebird bio reduced its workforce by about 25%, impacting nearly 100 employees from a headcount of 375 1 Tome Biosciences laid off 131 employees, suspected to account for the majority or all of its staff 1 Overall biotech layoffs in 2024 totaled 187 announced cuts, representing a 57% increase compared to 119 in 2023 1 Multiple companies including Lyra Therapeutics (87 employees), BioMarin (170 employees), and Akari Therapeutics (67% workforce reduction) announced major restructurings in 2024 1 Sources: 1. https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024

Fierce Biotech Fundraising Tracker '24: Tasca Raises $52M and Citryll Secures $89M

on

Recent Advances in Wearable Biosensor Development Programs in 2026

on

Fierce Biotech Layoff Tracker 2026: Amgen Lays Off 22 Horizon Staffers

on

Voyager Therapeutics Pauses Alzheimer's APOE Program 8 Months After Unveiling

on

NAMs-Related Presentations at the Upcoming 65th SOT Annual Meeting in San Diego

on

Ipsen Withdraws Tazverik from Market Due to Secondary Malignancy Safety Concerns

on

BMS Receives FDA Approval for Sotyktu in Psoriatic Arthritis Treatment

on

Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer

on

Incyte Receives FDA CRL for Zynyz NSCLC Expansion Due to Issues at Novo Nordisk's Catalent Indiana Facility, Becoming Third Affected Company

on

FDA Approves Leucovorin for Rare Cerebral Folate Deficiency Without New Trial Data

on

Novo Nordisk Receives FDA Warning Letter for Failing to Report Ozempic Safety Signals Including Deaths

on

Capricor Shares Rise as FDA Sets August 2026 Decision Date for Deramiocel in Duchenne Muscular Dystrophy After Prior Rejection

on